The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients ...
Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.
Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...
The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.
HealthDay News — In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are ...
Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...
GlobalData on MSN3d
Sanofi kicks off share buyback plan with $3bn L’Oréal stake purchaseL'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.
Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback